Erlotinib Completed Phase 2 Trials for Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00466687Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma